trending Market Intelligence /marketintelligence/en/news-insights/trending/-qq6Q5FKfP7uhOUrdZvObA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Everstone to invest US$50M in KKR-backed Slayback Pharma

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption

Street Talk Podcast

Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4

Street Talk Podcast

Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief

Everstone to invest US$50M in KKR-backed Slayback Pharma

Asia-focused private equity firm Everstone Capital Asia Pte Ltd. agreed to invest up to US$50 million in a series B funding round in KKR & Co. Inc.-backed pharmaceutical company Slayback Pharma LLC.

Along with the investment, Everstone's managing directors Arjun Oberoi and Puncham Mukim will join Slayback's board.

The capital will be used to expand and accelerate Slayback's differentiated line of pharmaceutical products.

KKR invested US$60 million in Slayback in December 2016.